Bank of America spends over $250 million on GLP-1 weight-loss drugs for its 210,000 employees

Bank of America's $250 Million GLP-1 Spending Spree

Bank of America CEO Brian Moynihan revealed the bank now spends more than $250 million annually on GLP-1 weight-loss medications for its 210,000-plus employees. Speaking at the Aspen Economic Strategy Group annual meeting, Moynihan characterized the outlay as a strategic health investment, even as it represents over 12% of the company’s roughly $2 billion annual healthcare budget.

The drugs — best known as Ozempic and Wegovy — have surged in demand for weight loss, pushing employers to weigh the immediate expense against potential long-term savings. Moynihan argued that the payoff includes reduced risks of heart disease and other chronic conditions, calling it “the right thing to do” despite acknowledging that some workers may leave before reaping the full benefits.

The stance puts BofA in a minority position. A 2026 survey by the International Foundation of Employee Benefit Plans found only 36% of employers cover GLP-1s for both diabetes and weight loss. Others, including consulting giant PwC, have reportedly stopped covering the drugs for weight loss, citing unsustainable costs. BofA, meanwhile, said it is working to get the medications as cheaply as possible — a goal that could be helped by the introduction of oral pill versions.

Why BofA Sees Long-Term Value in Covering Weight-Loss Drugs

The BofA Calculus: Costs vs. Chronic Care

For Moynihan, the arithmetic is clear: GLP-1s aren’t just about weight loss — they’re a frontline defense against expensive-to-treat illnesses like heart disease. By spending $250 million now, the bank hopes to avoid far larger long-term healthcare claims. It’s a wager that parallels how many companies invest in preventive care, though here the price tag is exceptionally high.

Yet the gamble has a retention risk. Moynihan admitted some employees will leave the bank before the medication can improve their health, meaning BofA foots the bill without seeing the payoff. It’s a rare case of a CEO publicly prioritizing long-term social value over immediate ROI — a position that could spark debate among investors focused on quarterly expenses.

The Broader Employer Divide

BofA’s approach contrasts with the two-thirds of companies that don’t cover GLP-1s for weight loss. The 2026 survey figure underscores a broader hesitation: while the drugs are clinically effective, their annual list price can exceed $1,000 per month per person. PwC’s reported decision to drop coverage for weight loss highlights how even large, benefit-rich employers are drawing lines.

For companies like BofA that stay in, the competitive advantage is clear — in a tight labor market, comprehensive weight-loss coverage can be a talent attraction and retention tool. That may explain why Moynihan frames the spending as a benefit investment rather than a pure health expense.

The Pill Promise

Moynihan’s comment about getting drugs “as cheaply as possible” and the arrival of oral forms signals a potential cost breakthrough. Injectable GLP-1s come with cold-chain logistics and higher manufacturing costs; pills could reduce per-patient spending dramatically. If BofA can negotiate bulk pricing for the oral alternatives, the bank may lower its $250 million run rate — making the program more sustainable and giving cover to other employers considering similar moves.

Employer Playbook: What BofA's Bet Means for GLP-1 Coverage Decisions

Employers evaluating GLP-1 coverage can draw several practical lessons from BofA’s experience:

• Model the offset. Moynihan bets that reduced heart disease and other chronic risks will offset the upfront cost. Run your own claims data to estimate whether fewer cardiovascular events or diabetes complications could make the math work.
• Watch the pill pipeline. With oral versions emerging, negotiate aggressively for lower per-unit prices. BofA explicitly aims to cut costs, suggesting that even a company spending $250 million sees room for savings.
• Leverage the talent angle. With only 36% of companies covering the drugs, comprehensive GLP-1 coverage can be a differentiator. In knowledge-economy sectors, the benefit may help attract and keep top performers.
• Plan for continuity. If you offer coverage, be cautious about changing it. The article notes that some workers faced financial strain after losing coverage — a scenario that can create HR headaches and damage culture.